You Are Now Leaving the UPLIZNA Canada Website for Healthcare Professionals
The linked sites are not under the control of Amgen, and Amgen is not responsible for the content available on the linked sites. Such links do not imply Amgen's endorsement of material on any other site, and Amgen disclaims all liability with regard to your access to such linked websites. Amgen provides links to other Internet sites as a convenience to users, and access to such linked sites is at your own risk.
Safety Information
UPLIZNA® (inebilizumab for injection) is indicated as monotherapy for the treatment of adult patients with neuromyelitis optica spectrum disorders who are anti-aquaporin-4 immunoglobulin G (AQP4-IgG) seropositive.
Treatment should be administered under the supervision of a qualified healthcare professional.
Please click here for additional safety information and a link to the product monograph discussing:
- Contraindications in patients with hypersensitivity to UPLIZNA®, history of life-threatening infusion reactions to UPLIZNA®, severe active infection (e.g., chronic hepatitis B), active or untreated latent tuberculosis, history of progressive multifocal leukoencephalopathy (PML), severely immunocompromised state, or active malignancy.
- Relevant warnings and precautions regarding infusion reactions, infections, required screening for infections (hepatitis B/hepatitis C/tuberculosis), vaccination and premedication requirements, PML in patients treated with other B-cell-depleting antibodies, late neutropenia, immunizations, B-cell repletion time, monitoring of serum immunoglobulins, possible risk of malignancy, possible risk to fertility, contraception use, pregnant and breastfeeding women, pediatrics, and geriatrics.
- Conditions of clinical use, adverse reactions, drug interactions, and dosing instructions.
ARE YOU A HEALTHCARE PROFESSIONAL?
To access the site, please provide the required information to verify that you are a Canadian healthcare professional and create an account. Once validated, this account can be used to log in to all Amgen websites for Canadian healthcare professionals. Please use the first and last name registered with your professional college.
Amgen Canada is dedicated to providing support for you and your patients every step of the way. As part of our commitment, we offer Amgen Entrust Rare, a comprehensive Patient Support Program designed to assist patients taking UPLIZNA and their healthcare providers.
Questions?
Call Amgen Entrust Rare at 1-844-601-RARE ( 1-844-601-7273)
Monday to Friday, 8 am to 8 pm (ET)
Fax 1-888-343-0933
Email UPLIZNA@entrustrare.ca
Horizon Therapeutics Canada is dedicated to providing support for you and your patients every step of the way. As part of our commitment, we offer TranscendRare®, a comprehensive Patient Support Program designed to assist patients taking UPLIZNA® and their healthcare providers.
Questions?
Call TranscendRare® at 1-844-380-7850
Monday to Friday, 8 am to 8 pm (EST)
